Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J).
Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, Saito K, Sekiguchi N, Sato E, Kameda H, Iwata S, Mochizuki T, Amano K, Tanaka Y. Takeuchi T, et al. Among authors: sato e. Mod Rheumatol. 2008;18(5):447-54. doi: 10.1007/s10165-008-0077-5. Epub 2008 May 21. Mod Rheumatol. 2008. PMID: 18493716
Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H. Tanaka Y, et al. Among authors: sato e. Mod Rheumatol. 2014 May;24(3):399-404. doi: 10.3109/14397595.2013.843757. Epub 2013 Nov 5. Mod Rheumatol. 2014. PMID: 24252045
Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.
Tanaka E, Inoue E, Hoshi D, Shimizu Y, Kobayashi A, Sugimoto N, Shidara K, Sato E, Seto Y, Nakajima A, Momohara S, Taniguchi A, Yamanaka H. Tanaka E, et al. Among authors: sato e. Mod Rheumatol. 2015 Jul;25(4):503-13. doi: 10.3109/14397595.2014.1001475. Epub 2015 Feb 11. Mod Rheumatol. 2015. PMID: 25547018
Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
Tanaka E, Inoue E, Yamaguchi R, Shimizu Y, Kobayashi A, Sugimoto N, Hoshi D, Shidara K, Sato E, Seto Y, Nakajima A, Momohara S, Taniguchi A, Yamanaka H. Tanaka E, et al. Among authors: sato e. Mod Rheumatol. 2017 Mar;27(2):227-236. doi: 10.1080/14397595.2016.1205799. Epub 2016 Jul 29. Mod Rheumatol. 2017. PMID: 27472516
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2).
Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, Nawata M, Kameda H, Iwata S, Amano K, Yamanaka H. Tanaka Y, et al. Among authors: sato e. Mod Rheumatol. 2008;18(2):146-52. doi: 10.1007/s10165-008-0026-3. Epub 2008 Feb 19. Mod Rheumatol. 2008. PMID: 18283523 Free PMC article.
Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study.
Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, Takeuchi T. Kameda H, et al. Among authors: sato e. J Rheumatol. 2011 Aug;38(8):1585-92. doi: 10.3899/jrheum.110014. Epub 2011 May 15. J Rheumatol. 2011. PMID: 21572151 Free article. Clinical Trial.
1,960 results